Shape 21 Experience

     

    AI-Pathway Companion 

    Actionable insights for personalized care

    AI-Pathway Companion1, a CE marked2  clinical decision support solution, enables personalized and standardized care along care pathways in oncology, cardiology and infectious diseases3. The intelligent clinical decision support solution aims to facilitate diagnosis and therapeutic decisions with a clear goal: improving patient outcomes along disease-specific pathways4.

    AI Pathway Companion Diagnosing

    In 2020 we officially presented our first CE-marked pathway – Prostate Cancer1. Now we are expanding the portfolio and we are introducing the AI-Pathway Companion for non-small cell lung cancer5

    Through ongoing development and refinement of data interfaces, we aim to increase the number of disease parameters captured throughout the clinical pathway, thereby expanding the relevant data points with the goal of advancing cancer care. We are looking forward to partnering with even more healthcare institutions on optimizing the AI-Pathway Companion solution to their routine clinical practice and preferred lung cancer workflow.

    Lung cancer is the most diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths) among men and women combined6.

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13